Iobenguane I-131-avid unresectable pheo/para.
2 therapeutic doses ~500 mCi, 90+ days apart.
Injection for IV
None listed.
Thrombocytopenia (89%), Lymphopenia (82%), Neutropenia (63%), Anemia (61%), Fatigue (47%), Nausea (42%)
Consult the complete prescribing information for a comprehensive list of adverse reactions and their frequencies.
Catecholamine uptake drugs may interfere.
Consult the full prescribing information for pregnancy-related considerations.
Refer to prescribing information for lactation guidance.
Pediatric safety and efficacy information is detailed in the full label.
Dose modifications for organ impairment are specified in the complete prescribing information.
Radiopharmaceutical delivering I-131 beta radiation via norepinephrine transporter.
Whole-body t1/2: ~36-48h.
Clinical efficacy and safety data supporting the approval are available in the full prescribing information and from the clinical trials listed below.
Azedra has FDA-approved indications across the following cancer types covered on CancerDrugEvidence:
Azedra (iobenguane I-131) is an FDA-approved oncology agent. Refer to the full prescribing information for complete indication details.
Refer to the full prescribing information for dosing schedules, administration instructions, and dose modifications.
Radiopharmaceutical delivering I-131 beta radiation via norepinephrine transporter.
Thrombocytopenia (89%), Lymphopenia (82%), Neutropenia (63%), Anemia (61%), Fatigue (47%), Nausea (42%) Thrombocytopenia 89% Lymphopenia 82% Neutropenia 63% Anemia 61% Fatigue 47% Nausea 42%